In an announcement on the company’s website on Thursday (Oct. 3), Notion Capital Managing Partner Stephen Chandler said the firm has launched the fund in an effort “to be the ‘go to’ B2B SaaS investor in Europe.” The expects the fund to exceed $150 million
Chandler pointed to B2B startups like Tradeshift , CurrencyCloud, Paddle and other B2B players in Notion’s existing portfolio as it looks to expand its presence in the B2B space
“The fact is, B2B tech is about grit, resolve and endurance,” he stated. “Sales cycles are longer, customer acquisition costs are higher and you have to get more right for longer than many other areas of the tech industry.”
Were you following this:
Pro Rata - October 3, 2019 - Axios
The bottom line: Everyone is trying to feel their way in the dark, in the absence of a consistent narrative
• MetroCity Bankshares , a Doraville, Ga.-based bank with 19 branches, raised $26 million in its IPO. The company priced 1.94 million shares at $13.50 (below range), for an initial market cap of $342 million! Notion Capital Launches Fund For B2B SaaS | PYMNTS.com www.pymnts.com/news/ b2b -payments/2019/ ...Notion Capital Goes After B2B SaaS With Launch Of Newest Fund. ...Notion Capital Venture Fund IV, which will focus on investments in the B2B Software as a Service ( SaaS ) industry.!! It will trade on the Nasdaq (MCBS), and used Keefe Bruyette Woods as lead underwriter
🚑 Viela Bio, a Gaithersburg, Md.-based inflammation and autoimmune biotech, raised $150 million in its IPO. It priced 7.9 million shares at $19, versus plans to offer 7.5 million shares at $19-$21, and will trade on the Nasdaq (VIE). Goldman Sachs was lead underwriter! Notion Capital launches new a Gaithersburg, Md.-based inflammation and autoimmune biotech, raised $150 million in its IPO. It priced 7.9 million shares at $19, versus plans to offer 7.5 million shares at $19-$21, and will trade on the Nasdaq (VIE). Goldman Sachs was lead underwriter50M fund aimed at European ...techcrunch.com /2019/10/03/ notion - capital ...Notion Capital today announced a new a Gaithersburg, Md.-based inflammation and autoimmune biotech, raised $150 million in its IPO. It priced 7.9 million shares at $19, versus plans to offer 7.5 million shares at $19-$21, and will trade on the Nasdaq (VIE). Goldman Sachs was lead underwriter50 million fund in a bid to bolster its claim to being the go -to investor for European B2B tech. Launched 10 years ago after the $700 million exit of ...!! Viela spun out of AstraZeneca in 2017 and raised $250 million in Series A funding from 6 Dimensions Capital, Boyu Capital, Hillhouse Capital, Temasek, and Sirona Capital.
London-based @NotionVC launches new $150M fund aimed at European B2B tech 💰 https://t.co/aIw7NeVwGX TechNation (from United Kingdom) Thu Oct 03 16:31:00 +0000 2019
No comments:
Post a Comment